Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.

TitleMultisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.
Publication TypeJournal Article
Year of Publication2020
AuthorsDiorio C, Henrickson SE, Vella LA, McNerney KO, Chase JM, Burudpakdee C, Lee JH, Jasen C, Balamuth F, Barrett DM, Banwell B, Bernt KM, Blatz AM, Chiotos K, Fisher BT, Fitzgerald JC, Gerber JS, Gollomp K, Gray C, Grupp SA, Harris RM, Kilbaugh TJ, John AROdom, Lambert MP, Liebling EJ, Paessler M, Petrosa W, Phillips CA, Reilly AF, Romberg N, Seif AE, Sesok-Pizzini D, Sullivan K, Vardaro J, Behrens EM, Teachey DT, Bassiri H
JournalJ Clin Invest
Date Published2020 Jul 30
ISSN1558-8238
Abstract

BACKGROUND: Initial reports from the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) pandemic described children as being less susceptible to Coronavirus Disease 2019 (COVID-19) than adults. Subsequently, a severe and novel pediatric disorder termed Multisystem Inflammatory Syndrome in Children (MIS-C) emerged. We report on unique hematologic and immunologic parameters that distinguish between COVID-19 and MIS-C and provide insight into pathophysiology.

METHODS: We prospectively enrolled hospitalized patients with evidence of SARS-CoV-2 infection and classified them as having MIS-C or COVID-19. Patients with COVID-19 were classified as having either minimal or severe disease. Cytokine profiles, viral cycle thresholds (Cts), blood smears, and soluble C5b-9 values were analyzed with clinical data. Twenty patients were enrolled (9 severe COVID-19, 5 minimal COVID-19, and 6 MIS-C). Five cytokines (IFN-γ, IL-10, IL-6, IL-8 and TNF-α) contributed to the analysis. TNF-α and IL-10 discriminated between patients with MIS-C and severe COVID-19. Cts and burr cells on blood smears also differentiated between patients with severe COVID-19 and those with MIS-C.

CONCLUSION: Pediatric patients with SARS-CoV-2 are at risk for critical illness with severe COVID-19 and MIS-C. Cytokine profiling and examination of peripheral blood smears may distinguish between patients with MIS-C and severe COVID-19.

DOI10.1172/JCI140970
Alternate JournalJ. Clin. Invest.
PubMed ID32730233